This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. PSTV, PETV, ICU, PAVM, BTCY, ALUR, SSKN, CODX, NURO, and INBSShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Plus Therapeutics (PSTV), PetVivo (PETV), SeaStar Medical (ICU), PAVmed (PAVM), Biotricity (BTCY), Allurion Technologies (ALUR), STRATA Skin Sciences (SSKN), Co-Diagnostics (CODX), NeuroMetrix (NURO), and Intelligent Bio Solutions (INBS). These companies are all part of the "medical" sector. Obalon Therapeutics vs. Plus Therapeutics PetVivo SeaStar Medical PAVmed Biotricity Allurion Technologies STRATA Skin Sciences Co-Diagnostics NeuroMetrix Intelligent Bio Solutions Plus Therapeutics (NASDAQ:PSTV) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking. Do institutionals & insiders have more ownership in PSTV or OBLN? 3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 5.5% of Plus Therapeutics shares are owned by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PSTV or OBLN? Obalon Therapeutics received 174 more outperform votes than Plus Therapeutics when rated by MarketBeat users. However, 63.72% of users gave Plus Therapeutics an outperform vote while only 46.68% of users gave Obalon Therapeutics an outperform vote. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Obalon TherapeuticsOutperform Votes24646.68% Underperform Votes28153.32% Which has more risk & volatility, PSTV or OBLN? Plus Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Which has higher valuation and earnings, PSTV or OBLN? Obalon Therapeutics has lower revenue, but higher earnings than Plus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M2.25-$13.32M-$2.50-0.26Obalon Therapeutics$1.59M2.13-$12.33MN/AN/A Does the media prefer PSTV or OBLN? In the previous week, Plus Therapeutics had 1 more articles in the media than Obalon Therapeutics. MarketBeat recorded 1 mentions for Plus Therapeutics and 0 mentions for Obalon Therapeutics. Plus Therapeutics' average media sentiment score of 1.89 beat Obalon Therapeutics' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Plus Therapeutics Very Positive Obalon Therapeutics Neutral Is PSTV or OBLN more profitable? Plus Therapeutics has a net margin of -225.07% compared to Obalon Therapeutics' net margin of -776.76%. Plus Therapeutics' return on equity of 0.00% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-225.07% N/A -154.56% Obalon Therapeutics -776.76%-161.38%-83.58% Do analysts recommend PSTV or OBLN? Plus Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 1,668.96%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Plus Therapeutics is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPlus Therapeutics beats Obalon Therapeutics on 11 of the 17 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.39M$4.33B$5.53B$7.93BDividend YieldN/A39.93%5.11%4.22%P/E Ratio-0.2530.0322.5118.54Price / Sales2.1355.31397.62103.34Price / CashN/A51.0838.1834.62Price / Book0.566.056.734.25Net Income-$12.33M$68.71M$3.22B$248.18M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$0.34-1.7%N/A+107.5%$3.39M$1.59M-0.252PSTVPlus Therapeutics2.5833 of 5 stars$0.84+7.1%$11.50+1,262.4%-58.7%$14.35M$4.91M-0.3320Positive NewsPETVPetVivoN/A$0.56+2.8%N/A-24.1%$13.56M$1.05M-1.2420Gap DownICUSeaStar Medical0.6426 of 5 stars$1.27+0.8%N/A-89.3%$12.45M$135,000.00-0.112Short Interest ↓News CoveragePAVMPAVmed4.4114 of 5 stars$0.72-5.3%$19.50+2,608.3%-63.8%$12.31M$3.00M-0.1790Short Interest ↓Gap UpBTCYBiotricityN/A$0.46+0.0%N/A-66.4%$11.46M$12.06M-0.4340Gap UpALURAllurion Technologies3.426 of 5 stars$2.38-0.8%$22.83+859.0%-95.2%$11.42M$32.11M-0.20501Positive NewsGap DownSSKNSTRATA Skin Sciences3.5167 of 5 stars$2.61-0.2%$6.00+129.5%-40.9%$10.90M$33.56M-0.98120Short Interest ↓Gap UpCODXCo-Diagnostics4.3206 of 5 stars$0.37+6.0%$5.50+1,382.1%-69.7%$10.43M$3.92M-0.27100Upcoming EarningsAnalyst ForecastNews CoverageGap UpNURONeuroMetrix0.4081 of 5 stars$4.39+1.0%N/A-0.2%$9.03M$3.03M-0.9620Analyst ForecastNews CoverageGap UpINBSIntelligent Bio Solutions0.4272 of 5 stars$1.28-0.8%N/A-52.4%$8.72M$3.03M0.0010 Related Companies and Tools Related Companies PSTV Competitors PETV Competitors ICU Competitors PAVM Competitors BTCY Competitors ALUR Competitors SSKN Competitors CODX Competitors NURO Competitors INBS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBLN Stock Free OBLN Stock Alerts